Daix (France), Long Island City (New York, United States), January 10, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of non-alcoholic steatohepatitis (“NASH”) and other diseases with a significant unmet medical need, today announces the drawing of the second tranche of €25 million of the loan unsecured granted by the European Investment Bank (EIB) on May 16, 2022 (the “Financing Contract”), the maturity of which will occur around January 18, 2027. The disbursement of the second tranche is scheduled for the 18 January 2024. On January 4, 2024, in accordance with the Financing Agreement, the Company issued 3,144,654 share subscription warrants reserved for the EIB.